Visual field defects associated with vigabatrin therapy

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 6, 1999, Pages 716-722

  Lawden, M C ^a   Eke, T ^a   Degg, C ^a   Harding, G F A ^b   Wild, J M ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Retina; Vigabatrin; Visual field

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; ETHOSUXIMIDE; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; SULTIAME; TOPIRAMATE; TRIMETHADIONE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAM; EPILEPSY; EVOKED VISUAL RESPONSE; EYE TOXICITY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; VISUAL FIELD; VISUAL FIELD DEFECT;

EID: 0032721611     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.6.716     Document Type: Article

References (39)

1. Dieterle L, Becker EW, Berg PA, et al. Allergische Vaskulitis durch Vigabatrin. Nervenarzt 1994;65:122-4.
2. Faedda MT, Giallonardo AT, Marchetti A, et al. Terapia con vigabatrin nelle epilessie parziali resistenti. G Neuropsicofarmacol 1993;15:105-8.
3. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314: 180-1.
4. Wilson EA, Brodie MJ. Chronic refractory epilepsy may have role in causing these unused lesions. BMJ 1997;314: 1693.
5. Wong ICK, Mawer E, Sander WAS. Reaction might be close dependent. BMJ 1997;314:1693-4.
6. Blackwell N, Hayllar J, Kelly G. Patients taking vigabatrim should have regular visual field testing. BMJ 1997;314: 1694.
7. Harding GFA. Four possible explanations exist. BMJ 1997; 314:1694.
8. Kramer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia 1997;38(suppl 8):179.
9. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrim BMJ 1998;316:233.
10. Lawden MC, Eke T, Degg C, et al. Visual field abnormalities in epileptic patients taking the anticonvulsant vigabatrin. Neuroophthalmology 1997;18(suppl):17.
11. Harding G, Lawden M, Wild J, et al. Visual defects in patients receiving AEDs. Epilepsia 1997;38(suppl 3):67.
12. Harding G, Wild J, Robertson K, et al. Electrooculography, ERGs, multi-focal ERGs and VEPs in epileptic patients showing visual field disorders [[abstract]]. Electroencephalogr Clin Neurophysiol 1997;103:96.
13. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmic findings. Neurology 1998;50:614-8.
14. Kälviäinen R, Nousiainen I, Nikoskelainen E, et al. Visual field defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine monotherapy [[abstract]]. Epilepsia 1998;39(suppl 2):5.
15. Black AB. Vigabatrin and visual field loss [[abstract]]. Epilepsia 1998;39(suppl 2):5-6.
16. Beran RG, Currie J, Sandbach J, et al. Visual field restriction with new antiepileptic medication [[abstract]]. Epilepsia 1998;39(suppl 2):6.
17. Pung T, Ruether K, Schmitz B, et al. Visual field restriction during treatment with vigabatrin [[abstract]]. Epilepsia 1998;39(suppl 2):40-1.
18. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998;116: 817-9.
19. Rao GP, Ah Fat F, Kyle G, et al. Study is needed of visual field defects associated with any long term antiepileptic drug. BMJ 1998;317:206.
20. Ludwig BL, Marsan CA. Clinical ictal patterns in epileptic patients with occipital electroencephalographic foci. Neurology 1975;25:463-71.
21. Lorenz R, Kuck H. Visuelle Störungen durch Diphenylhydantoin: Klinische und elektroophthalmologische Befunde. Klin Monatsbl Augenheilkd 1988;192:244-7.
22. Elder MJ. Diazepam and its effects on visual fields. Aust N Z J Ophthalmol 1992;20:267-70.
23. Paulus W, Schwarz G, Steinhoff BJ. The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Brain 1996;119:539-49.
24. Baulac M, Nordmann JP, Lanoé Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.
25. Wu S, Sutter EE. A topographic study of oscillatory potentials in man. Vis Neurosci 1995;12:1013-25.
26. Harding GFA, Jones LA, Tipper VJ, et al. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995;36:S108.
27. Duckett T, Brigell MG, Ruckh S. Electroretinographic changes are not associated with loss of visual function in pediatric epileptic patients following treatment with vigabatrin. Invest Ophthalmol Vis Sci 1998;39:S973.
28. John RA, Rimmer EM, Williams J, et al. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol 1987;36:1467-73.
29. Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38
30. Graham D. Neuropathology of vigabatrin. British Journal of Clinical Pharmacology 1989;27:43S-5S.
31. Pedersen B, Højgaard K, Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res 1987;1:74-6.
32. Mauguiere F, Chauvel P, Dewailly J, et al. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997;38:301-8.
33. Crofts K, Brennan R, Kearney P, et al. Vigabatrin-induced optic neuropathy. J Neurol 1997;10:666-7.
34. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-hooded rats. Toxicol Pathol 1987;15:143-8.
35. Marc RE. Structural organization of GABAergic circuitry in ectotherm retinas. In: Mize RR, Marc RE, Sillito AM, eds. Progress in brain research. Vol 90. GABA in the retina and central nervous system. Amsterdam: Elsevier, 61-92.
36. A agonists. Vis Neurosci 1995;12: 641-50.
37. Neal MJ, Cunningham JR, Shah MA, et al. Immuhocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 1989; 98:29-32.
38. Cubells JF, Blanchard JS, Smith DM, et al. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina v brain. J Pharmacol Exp Ther 1986;238:508-14.
39. Neal MJ, Shah MA. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol 1990;100:324-8.